NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
43
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,148.90 | 93.60 | 1.16% |
| CAC 40 | 8,111.89 | 59.58 | -0.73% |
| DAX 40 | 22,998.21 | 289.85 | -1.24% |
| Dow JONES (US) | 42,161.81 | 197.18 | 0.47% |
| FTSE 100 | 8,703.93 | 2.73 | -0.03% |
| HKSE | 24,219.95 | 551.19 | -2.23% |
| NASDAQ | 17,865.56 | 114.77 | 0.65% |
| Nikkei 225 | 37,751.88 | 93.54 | -0.25% |
| NZX 50 Index | 12,054.72 | 8.79 | 0.07% |
| S&P 500 | 5,700.97 | 25.68 | 0.45% |
| S&P/ASX 200 | 7,918.90 | 90.60 | 1.16% |
| SSE Composite Index | 3,408.95 | 17.48 | -0.51% |